<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;utm_campaign=journals&amp;ff=2 02502220071941＆utm_medium = rss＆utm_source = chrome＆utm_content = 101560960＆v = 2.18.0.post9+e462414＆fc = none<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;ff=20250220071941&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414&amp;fc=None" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> THU，2025年2月20日12:19:42 +0000</lastbuilddate><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>肾脏疾病中的铁和铁凋亡：分子和代谢机制</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975561/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>维持铁稳态对于肾脏功能是必需的。越来越多的研究表明肾脏疾病通常是铁不平衡引起的。在过去的十年中，铁凋亡在介导肾脏疾病的发育和进展中的作用，例如急性肾脏损伤（肾脏缺血 - 重新灌注损伤，药物诱发的急性肾脏损伤，严重的急性胰腺炎，诱导的急性肾脏损伤和SEPSIS相关急性肾脏肾脏损伤损伤），慢性肾脏疾病（糖尿病... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1531577。 doi：10.3389/fimmu.2025.1531577。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">维持铁稳态对于肾脏功能是必需的。越来越多的研究表明肾脏疾病通常是铁不平衡引起的。在过去的十年中，铁凋亡在介导肾脏疾病的发育和进展中的作用，例如急性肾脏损伤（肾脏缺血 - 重新灌注损伤，药物诱发的急性肾脏损伤，严重的急性胰腺炎，诱导的急性肾脏损伤和SEPSIS相关急性肾脏肾脏损伤损伤），慢性肾脏疾病（糖尿病性肾病，肾纤维化，常染色体显性多囊性肾脏疾病）和肾细胞癌已成为焦点。因此，了解肾铁代谢和铁凋亡调节可能会增强疾病疗法。在这篇综述中，我们讨论了肾脏疾病中铁信号传导和铁凋亡的代谢和分子机制。我们还探讨了肾脏疾病治疗中铁凋亡的可能靶标，以及他们现有的局限性和未来策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975561/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975561</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835690/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835690</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1531577>10.3389/fimmu.2025.1531577</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975561</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Wenjie Wang</dc:creator><dc:creator> Jingdi Chen</dc:creator><dc:creator> Zhan</dc:creator><dc:creator> Handong Zou</dc:creator><dc:creator> Lu Wang</dc:creator><dc:creator>门芒郭</dc:creator><dc:creator>挂高</dc:creator><dc:creator>Jing Xu</dc:creator><dc:creator> Wei Wu</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>肾脏疾病中的铁和铁凋亡：分子和代谢机制</dc:title><dc:identifier>PMID：39975561</dc:identifier><dc:identifier> PMC：PMC11835690</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1531577</dc:identifier></item><item><title>由ATF3/NRF2介导的肾上腺肾小管上皮细胞分泌的外泌体促进了M1/M2比率失衡，引起缺血和再灌注损伤后肾脏间质纤维化诱导肾脏间质纤维化</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975560/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>结论：ATF3可能通过抑制NRF2/是途径来加速螺旋病，而来自铁凋亡细胞的外泌体降低了M1/M2巨噬细胞比率，从而促进纤维化。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1510500。 doi：10.3389/fimmu.2025.1510500。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：严重的肾脏缺血和再灌注损伤（IRI）发展到具有有限的治疗策略的肾脏间隙纤维化（RIF）。尽管铁腐烂和巨噬细胞极化都在该模型中起重要作用，但尚未阐明它们的特定发病机理和相互作用。因此，我们旨在探讨肾小管上皮细胞（RTEC）和甲状腺毒细胞衍生的外泌体在IRI相关RIF模型中诱导巨噬细胞极化的机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：<i>在体内</i>，C57BL/6J小鼠被随机分为四组：假手术组，缺血和再灌注（IR）组，IR + Ferrostatin-1（FER-1）组和IR + ATF3敲低（ATF <sup>KD</sup> ）组。<i>在体外</i>，将RTEC分为对照组（CON）组，缺氧/re氧（HR）组，HR + FER-1组，HR + SIRNA-ATF3（SIATF3）组。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与假手术组相比，IR组在HE染色，Masson染色中更多的胶原蛋白纤维和免疫组织化学中较高的α-SMA表达水平更为严重。总铁和MDA含量增加，而GSH含量降低。与假手术组相比，IR组具有更明显的线粒体损伤和更高的PTGS2和TFRC mRNA水平。与IR组相比，上述指数均在IR+FER-1或IR+ATF3 <sup>KD</sup>组中缓解。此外，IR组中ATF3，NRF2和HO-1的蛋白质表达比假模组中的蛋白质表达增加。与IR组相比，IR+FER-1或IR+ATF3 <sup>KD</sup>组中的ATF3表达减少，NRF2和HO-1的蛋白质含量进一步增加。此外，IR组中的M2标记水平（ARG1，TGF-β和IL-10 mRNA）比假手术组中的水平较高，而IR+FER-1组或IR+ATF3 <sup>kd</sup>中的水平更高组与IR组相比。<i>体外</i>实验的结果与<i>体内</i>实验的结果一致。从机械上讲，HR组携带miR-1306-5p的外泌体释放促进了更多的M2巨噬细胞。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：ATF3可能通过抑制NRF2/是途径来加速螺旋病，而来自铁凋亡细胞的外泌体降低了M1/M2巨噬细胞比率，从而促进纤维化。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975560/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975560</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835872/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835872</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1510500>10.3389/fimmu.2025.1510500</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975560</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Qiao Tang</dc:creator><dc:creator> Jiatao Xie</dc:creator><dc:creator> Yifei Wang</dc:creator><dc:creator>郑宗</dc:creator><dc:creator>Qian Sun</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>由ATF3/NRF2介导的肾上腺肾小管上皮细胞分泌的外泌体促进了M1/M2比率失衡，引起缺血和再灌注损伤后肾脏间质纤维化诱导肾脏间质纤维化</dc:title><dc:identifier>PMID：39975560</dc:identifier><dc:identifier> PMC：PMC11835872</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1510500</dc:identifier></item><item><title>泪腺超声检查在评估慢性眼移动 - 主持疾病中的应用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975559/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>结论：OGVHD患者的眼部表面状况比非GVHD患者观察到的眼部状况要差。主要表现包括角膜结束损伤以及泪液分泌和泪膜稳定性的降低。这些作用似乎是化学放疗引起的炎症和反应相关反应的常见结果。超声检查显示，泪腺的形态没有显着差异。这表明眼部拒绝可能不是... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1490390。 doi：10.3389/fimmu.2025.1490390。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：研究富腺超声检查在评估同种异体造血干细胞移植后（Allo-HSCT）之后的慢性眼移植 - 抗宿主 - 疾病（OGVHD）的有效性，并在眼表面和超声检查结果之间建立相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：横断面研究包括57名18岁及以上的参与者，他们在Allo-HSCT之后至少100天。该研究是在2023年3月至2023年6月之间在北京大学人民医院的OGVHD诊所进行的。根据国际慢性OGVHD（ICCGVHD）共识组诊断标准或2005年国家卫生研究院（NIH）的分类标准，将患者分组为组。慢性GVHD。收集了所有参与者的人口统计学和与移植相关的信息，包括年龄，性别，供体 - 竞争者HLA匹配，供体 - 竞争者ABO匹配，供体 - 亲戚的性别组合和Allo-HSCT后持续时间。使用各种参数，例如眼表面疾病指数（OSDI），Schirmer测试，撕裂膜破裂时间（但），泪液拟态，角膜/结膜染色和梅博莫利亚，评估了OGVHD的疾病活性和眼表面受累的严重程度腺辍学。通过B模式和多普勒超声检查评估泪腺结构，以测量参数，例如长直径，厚直径，同质性和实质血管化。进行了统计分析，以确定组之间的眼表面条件​​和泪腺超声参数的差异，并确定眼部表面条件与泪腺超声检查结果之间的相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：（1）与非OGGVHD患者相比，Allo-HSCT后有明确且可能的OGVHD患者表现出明显更长的持续时间（H = 11.264，P &lt;0.01），中位持续时间为247（164,894）天（164,894）天和525（310,928）（310,928）非OGVHD患者分别为204天（169,323.25）天。 （2）与非OGVHD患者相比，确定的OGVHD患者和可能的OGVHD患者均显示出较低的Schirmer检测平均水平（H = 31.188，P &lt;0.01），TBUT（H = 11.853，P &lt;0.01），泪液囊囊均高度（H泪液囊囊肿（H） = 13.630，p &lt;0.01）和更高的OSDI平均值（F = 27.992，P &lt;0.01），角膜染色评分（χ²= 23.66，p &lt;0.05）和时间结膜染色评分（χ²= 14.84，p &lt;0.05）。 （3）泪腺中的B模式和多普勒超声检查参数，包括长直径，厚直径，同质性和实质性血管形成，这两组之间没有显着差异。 （4）泪类超声检查中的长直径与泪液拟周术高度（r = 0.297，p &lt;0.05）具有显着正相关，并且与时间结膜染色评分（r = -0.313，p &lt;0.05）和染色总分（p &lt;0.05）和总分（ r = -0.285，p &lt;0.05）。泪超声检查中的厚直径表现出与泪液拟周术高度（r = 0.404，p &lt;0.01）的显着正相关，并且与OSDI显着负相关（r = -0.273，p &lt;0.05），角膜染色得分（R = -0.264，，r = -0.264，，，p &lt;0.05） p &lt;0.05），鼻结膜染色评分（r = -0.271， p &lt;0.05）和染色总得分（r = -0.312，p &lt;0.05）。均匀性和实质血管形成未发现与眼部表面状态显着相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：OGVHD患者的眼部表面状况比非GVHD患者观察到的眼部状况要差。主要表现包括角膜结束损伤以及泪液分泌和泪膜稳定性的降低。这些作用似乎是化学放疗引起的炎症和反应相关反应的常见结果。超声检查显示，泪腺的形态没有显着差异。这表明眼部排斥可能不是OGVHD患者泪腺变化的主要原因。尽管超声检查可以洞悉泪液分泌，但其在诊断OGVHD方面的功效似乎有限。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975559/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975559</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11836017/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11836017</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1490390>10.3389/fimmu.2025.1490390</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975559</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Mingxia Zhong</dc:creator><dc:creator> Siyuan Liu</dc:creator><dc:creator> Jinghan Luo</dc:creator><dc:creator>秦朝</dc:creator><dc:creator>周阳</dc:creator><dc:creator>Shanshan Zhang</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>泪腺超声检查在评估慢性眼移动 - 主持疾病中的应用</dc:title><dc:identifier>PMID：39975559</dc:identifier><dc:identifier> PMC：PMC11836017</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1490390</dc:identifier></item><item><title>血液恶性肿瘤中刺激表达的生物信息学表征揭示了预后和抗肿瘤免疫的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975558/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>简介：干扰素反应CGAMP相互作用器（STING）的刺激剂对于先天和适应性免疫都是必不可少的。但是，缺乏对血液系统恶性肿瘤的刺痛表达的全面分子表征。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1477100。 doi：10.3389/fimmu.2025.1477100。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：干扰素反应CGAMP相互作用器（STING）的刺激剂对于先天和适应性免疫都是必不可少的。但是，缺乏对血液系统恶性肿瘤的刺痛表达的全面分子表征。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，使用GTEX，CCLE，HEMAP和TCGA数据库鉴定了与STING表达相关的泛血癌景观，并研究了预测预后的潜在价值。在Hemap数据库中评估了STING表达与免疫细胞富集之间的关系。此外，使用肿瘤免疫功能障碍和排除（TIDE）生物标志物和现实世界免疫疗法数据集对预测免疫疗法疗效的刺激值进行了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果和讨论：发现刺激在急性髓样白血病（AML）和慢性髓样白血病中相对高度表达，较高的刺激表达与AML的预后较差相关。 STING表达与免疫相关途径（例如IFN-GAMMA反应，IFN-Alpha反应和炎症反应）正相关。在某些血液学肿瘤中，尤其是慢性淋巴细胞性白血病和地幔细胞淋巴瘤，细胞溶解评分和刺激表达呈正相关。有趣的是，STING表达与AML中的潮汐生物标志物负相关，这表明AML表达水平高的AML患者可能受益于免疫治疗。我们的发现促进了血液学恶性肿瘤刺激的分子表征，从而促进了个性化预后和治疗策略的发展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975558/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975558</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835856/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835856</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1477100>10.3389/fimmu.2025.1477100</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975558</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xiang-Mei Wen</dc:creator><dc:creator> Zi-Jun Xu</dc:creator><dc:creator> Ji-Chun MA</dc:creator><dc:creator> Min-Jie Zhang</dc:creator><dc:creator>你们</dc:creator><dc:creator>江林</dc:creator><dc:creator>Jun Qian</dc:creator><dc:creator> Yuan-Yuan fang</dc:creator><dc:creator> Shu-Yu Luo</dc:creator><dc:creator> Zhen-Wei毛</dc:creator><dc:date>2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>血液恶性肿瘤中刺激表达的生物信息学表征揭示了预后和抗肿瘤免疫的关联</dc:title><dc:identifier>PMID：39975558</dc:identifier><dc:identifier> PMC：PMC11835856</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1477100</dc:identifier></item><item><title> NAD+代谢与免疫细胞浸润之间的相互作用：新型诊断模型的亚型鉴定和发展</title><link/>https://pubmed.ncbi.nlm.nih.gov/3997557/?utm_source=Chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>结论：我们的研究揭示了UC中的两个NAD+亚型，鉴定了四个用于亚型的生物标志物，两种生物标志物进行诊断。这些发现可以表明潜在的治疗靶标，并有助于推进UC的个性化治疗策略，从而有可能改善患者的预后。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1479421。 doi：10.3389/fimmu.2025.1479421。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：溃疡性结肠炎（UC）是全球发病率增加的结肠粘膜的慢性炎症性疾病。越来越多的证据凸显了烟酰胺腺苷二核苷酸（NAD+）代谢在UC发病机理中的关键作用，这促使我们研究了NAD+代谢相关基因（NMRGS）的亚型特异性分子基础和诊断潜力（NMRGS）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从UC患者和健康对照组中的转录组数据从GEO数据库下载，特别是GSE75214和GSE87466。我们基于差异表达的NAD+代谢相关基因（DE-NMRG）进行了无监督的聚类，以将UC病例分类为不同的亚型。 GSEA和GSVA确定了这些亚型中活性的潜在生物途径，而Cibersort算法评估了差异免疫细胞浸润。加权基因共表达网络分析（WGCNA）与差异基因表达分析相结合，用于查明UC中的特定NMRG。使用两种机器学习算法选择用于亚型和诊断的强大基因特征。构建了命名图，并使用接收器操作特征（ROC）曲线评估其有效性。进行了逆转录定量聚合酶链反应（RT-QPCR），以验证细胞系中的基因表达。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在我们的研究中，根据DE-NMRGS表达水平将UC患者分为两种亚型，在炎症反应过程中表现出增强的自我修复能力，并且B簇B显示出更大的炎症和组织损伤。通过全面的生物信息学分析，我们确定了四个关键的生物标志物（AOX1，NAMPT，NNMT，PTGS2）用于UC亚型，而两个（NNMT，PARP9）用于诊断。这些生物标志物与UC微环境（尤其是NAMPT和PTGS2）内的各种免疫细胞密切相关，这些免疫细胞与中性粒细胞浸润密切相关。用于亚型和诊断开发的诺夫图表现出很高的预测准确性，在训练集中达到曲线（AUC）值高达0.989和0.997，在验证集中最高为0.998和0.988。 RT-QPCR验证显示在发炎与正常结肠上皮中的NNMT和PARP9显着上调，强调了它们的诊断相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究揭示了UC中的两个NAD+亚型，鉴定了四个用于亚型的生物标志物，两种生物标志物进行诊断。这些发现可以表明潜在的治疗靶标，并有助于推进UC的个性化治疗策略，从而有可能改善患者的预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975557/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975557</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835821/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835821</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1479421>10.3389/fimmu.2025.1479421</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975557</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Linglin Tian</dc:creator><dc:creator> Huiyang Gao</dc:creator><dc:creator>天阳</dc:creator><dc:creator>Yuhao Chen</dc:creator><dc:creator> linna gao</dc:creator><dc:creator> Jingxiang Han</dc:creator><dc:creator> Lanqi Zhu</dc:creator><dc:creator>他黄</dc:creator><dc:date>2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>NAD+代谢与免疫细胞浸润之间的相互作用：新型诊断模型的亚型鉴定和发展</dc:title><dc:identifier>PMID：39975557</dc:identifier><dc:identifier> PMC：PMC11835821</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1479421</dc:identifier></item><item><title>血液微卫星不稳定性（BMSI）的动力学负担预测了接受免疫检查点抑制剂治疗的患者的结果：过度疾病的病例报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975556/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>微卫星不稳定性（MSI）是一种经过广泛研究的分子签名，与免疫检查点抑制剂治疗的患者的长期益处有关。事实证明，这种方法可有效治疗MSI阳性结直肠癌（CRC）的患者。串行液体活检样品的分析允许检测响应治疗的肿瘤变化。通常，体细胞突变用于追踪肿瘤的动力学，并评估... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1492296。 doi：10.3389/fimmu.2025.1492296。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">微卫星不稳定性（MSI）是一种经过广泛研究的分子签名，与免疫检查点抑制剂治疗的患者的长期益处有关。事实证明，这种方法可有效治疗MSI阳性结直肠癌（CRC）的患者。串行液体活检样品的分析允许检测响应治疗的肿瘤变化。通常，体细胞突变用于追踪肿瘤的动力学，并且目前尚未将MSI等DNA特征的评估用于这些目的。在这里，我们描述了MSI阳性CRC的病例，该病例接受了Nivolumab单一疗法。对患者血浆的顺序采样表明，MSI负担增加（BMSI），发现与驾驶员突变负担的增加相关，开始了Nivolumab后一个月的增加和过度疾病。因此，通过NGS进行液体活检中BMSI的分析可能是及时评估MSI阳性CRC患者接受的治疗有效性的有前途方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975556/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975556</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11836019/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11836019</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1492296>10.3389/fimmu.2025.1492296</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975556</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Daria Kravchuk</dc:creator><dc:creator>亚历山德拉·勒贝娃（Alexandra Lebedeva）</dc:creator><dc:creator> Olesya Kuznetsova</dc:creator><dc:creator>亚历山德拉·卡文（Alexandra Kavun）</dc:creator><dc:creator> Anastasiia Taraskina</dc:creator><dc:creator> Ekaterina Belova</dc:creator><dc:creator> Tatiana Grigoreva</dc:creator><dc:creator> Egor Veselovsky</dc:creator><dc:creator> Vladislav Mileyko</dc:creator><dc:creator>弗拉迪斯拉夫·尼古林</dc:creator><dc:creator>Lidia Nekrasova</dc:creator><dc:creator> Alexey Tryakin</dc:creator><dc:creator> Mikhail Fedyanin</dc:creator><dc:creator>马克西姆·伊万诺夫（Maxim Ivanov）</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>血液微卫星不稳定性（BMSI）的动力学负担预测了接受免疫检查点抑制剂治疗的患者的结果：过度疾病的病例报告</dc:title><dc:identifier>PMID：39975556</dc:identifier><dc:identifier> PMC：PMC11836019</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1492296</dc:identifier></item><item><title>肺移植中支气管相关的淋巴组织：排斥反应或耐受性调节剂？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39975555/?utm_source=Chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>支气管相关淋巴组织（BALT）在调节对移植肺部免疫反应中的作用仍然是一个引人注目的领域和争议。在大鼠肺移植模型中的早期研究表明，BALT可以通过诱导局部和全身性炎症反应来加速移植物的排斥。在大鼠的肺内气管内移植模型中证实了这种观察结果。虽然一些人类研究描述了在嫁接中存在的巴尔特... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1553533。 doi：10.3389/fimmu.2025.1553533。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">支气管相关淋巴组织（BALT）在调节对移植肺部免疫反应中的作用仍然是一个引人注目的领域和争议。在大鼠肺移植模型中的早期研究表明，BALT可以通过诱导局部和全身性炎症反应来加速移植物的排斥。在大鼠的肺内气管内移植模型中证实了这种观察结果。尽管一些人类研究描述了在被长期被拒绝的移植物中的存在，但其他人则没有观察到Balt诱导与不良后果之间的关联。最近的研究发现，富含免疫调节细胞群体的Balt是在耐受的小鼠肺同种异体移植物中诱导的，这表明这种结构可能可以防止排斥。因此，BALT在肺移植生物学中的作用很复杂。从研究侧重于BALT在肺移植中的作用的研究中获得的见解可能是可以利用的，以开发新的疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975555/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975555</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835794/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835794</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1553533>10.3389/fimmu.2025.1553533</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975555</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator>亚历山大·温·温（Alexander n Wein）</dc:creator><dc:creator>查尔斯·刘</dc:creator><dc:creator>丹尼尔·克雷塞尔（Daniel Kreisel）</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>肺移植中支气管相关的淋巴组织：排斥反应或耐受性调节剂？</dc:title><dc:identifier> PMID：39975555</dc:identifier><dc:identifier> PMC：PMC11835794</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1553533</dc:identifier></item><item><title>类风湿关节炎中肺纤维化和肺气肿的缔合与类风湿因子高滴度和自身免疫性与肺</title><link/>https://pubmed.ncbi.nlm.nih.gov/3997554/?utm_source=Chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>背景：肺纤维化和肺气肿（CPFE）通常与结缔组织疾病（CTD）共存，例如类风湿关节炎（RA）。但是，导致CTD-CPFE发展的危险因素在很大程度上仍然不明显。这项研究旨在使用大量连续的RA患者进行CPFE表征CPFE，并阐明与RA-CPFE发育相关的潜在危险因素。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1514552。 doi：10.3389/fimmu.2025.1514552。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：肺纤维化和肺气肿（CPFE）通常与结缔组织疾病（CTD）共存，例如类风湿关节炎（RA）。但是，导致CTD-CPFE发展的危险因素在很大程度上仍然不明显。这项研究旨在使用大量连续的RA患者进行CPFE表征CPFE，并阐明与RA-CPFE发育相关的潜在危险因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：总共976名RA患者参加了这项横断面研究，以表征RA-CPFE。进行了多次逻辑分析，以确定RA-CPFE开发的潜在风险因素。使用流式细胞仪评估了健康供体的原代人支气管上皮细胞（HBEC）的患者IgG和IgM自身抗体。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">研究结果：在976例RA患者中，有414（42.4％）出现间质肺疾病（ILD），有74例（7.6％）经历CPFE。与RA-CPFE肺气肿的RA-CPFE患者相比，具有肺气肿的肺气肿的患者具有较高的肺气肿评分和肺功能参数降低。多重逻辑回归分析表明，男性性别，吸烟，职业暴露于灰尘，高ILD评分，高风湿因子（RF）滴度以及抗SSA的存在与RA-CPFE的风险增加有关。此外，与健康对照组相比，RA-CPFE患者的IgG和IgM自身抗体水平升高，与RF水平正相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">解释：这项研究是第一个证明RA-CPFE与RF高滴度的关联以及对HBEC的自身抗体的关系，这表明自身免疫与肺部和RA-CPFE之间有联系。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975554/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975554</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11836040/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11836040</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1514552>10.3389/fimmu.2025.1514552</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975554</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> aiping ma</dc:creator><dc:creator> Renliang Huang</dc:creator><dc:creator> jiaxi guo</dc:creator><dc:creator>广东王</dc:creator><dc:creator>Heqing Huang</dc:creator><dc:creator> Xinze li</dc:creator><dc:creator> Shan Zhong</dc:creator><dc:creator> Yan Huang</dc:creator><dc:creator> Shaowei lin</dc:creator><dc:creator> Yikai Lin</dc:creator><dc:creator> Qiaomiao Zhou</dc:creator><dc:creator> Susanne Krauss-Etschmann</dc:creator><dc:creator>弗兰克·彼得森</dc:creator><dc:creator>Zhanxiang Wang</dc:creator><dc:creator> xinhua yu</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>类风湿关节炎中肺纤维化和肺气肿的缔合与类风湿因子高滴度和自身免疫性与肺</dc:title><dc:identifier>PMID：39975554</dc:identifier><dc:identifier> PMC：PMC11836040</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1514552</dc:identifier></item><item><title>开发和评估肠道三细胞模型，以研究消化食品的促/抗炎潜力</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975553/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>结论：这些发现证实了该模型评估食物消化对特定细胞因子和渗透率标志物的影响的可行性，这代表了研究食物在调节炎症反应中的作用的宝贵策略。获得的结果可能支持旨在促进健康和预防炎症相关的代谢疾病的饮食策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1545261。 doi：10.3389/fimmu.2025.1545261。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：已提出免疫原理，被定义为调节免疫系统活性的食物，营养和饮食模式的潜力，是一种提高代谢和免疫介导疾病中免疫反应的策略。但是，食物和饮食的抗/促炎作用尚待完全确定，因此，适当的体外细胞培养模型需要继续研究食物在调节细胞介导的炎症过程中的作用。这项研究旨在开发和测试一个体外三文化模型，模拟肠道的复杂性及其多个细胞相互作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：为实现这一目标，肠上皮屏障是通过共同培养的人CACO-2肠肠细胞样和HT29-MTX-E12粘液产生类似酒杯的结肠细胞的，然后将人类单核细胞THP THP THP THP THP THP THP THP THP-1细胞与基底外侧隔室中添加。监测上皮屏障的完整性和稳定性，并使用不同浓度的各种压力源（phorbol-12-霉菌差异13-乙酸盐或PMA），脂多糖或LPS（phorbol-12--霉菌酯13-乙酸盐或LPS）评估模型的炎症反应。在细胞因子生产方面。为了测试模型，将不同浓度的<i>体外</i>消化西兰花（BD）添加到模型的顶端部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：使用自动化ELISA（ELLA）收集了来自基底外侧室的上清液并分析细胞因子产生（IL-6，TNF-α，IL-12P70，IL-18和IL-8）。另外，通过流式细胞仪分析了来自上皮细胞紧密连接的ZO-1蛋白。结果表明，在整个模型中添加了100 nm PMA 20 h是模拟肠道温和炎症状态的最佳压力源。与对照组相比，在用BD处理后，IL-6，TNF-α，IL-8和IL-18处理后，ZO-1表达在最低的BD浓度下增加。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现证实了该模型评估食物消化剂对特定细胞因子和渗透率标志物的影响的可行性，这代表了研究食物在调节炎症反应中作用的宝贵策略。获得的结果可能支持旨在促进健康和预防炎症相关的代谢疾病的饮食策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975553/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975553</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835836/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835836</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1545261>10.3389/fimmu.2025.1545261</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975553</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator>玛丽娜·拉马尔·桑切斯（Marina Ramal-Sanchez）</dc:creator><dc:creator> Chiara Bravo-Trippetta</dc:creator><dc:creator> Veronica d&#39;Antonio</dc:creator><dc:creator> Elena Corvaglia</dc:creator><dc:creator> Angela AmKämpfer</dc:creator><dc:creator> Roel PF Schins</dc:creator><dc:creator>毛罗·塞拉菲尼（Mauro Serafini）</dc:creator><dc:creator> Donato Angelino</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>开发和评估肠道三细胞模型，以研究消化食品的促/抗炎潜力</dc:title><dc:identifier>PMID：39975553</dc:identifier><dc:identifier> PMC：PMC11835836</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1545261</dc:identifier></item><item><title>单细胞测序阐明了神经胶质瘤中NUSAP1的机制及其诊断和预后意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975552/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description>结论：基于NUSAP1的风险模型可作为个性化神经胶质瘤治疗的预测和治疗工具的潜力。对NUSAP1在胶质母细胞瘤中的机制的深入探索可以增强我们对其对免疫疗法反应的理解，这表明靶向NUSAP1可能会为神经胶质瘤患者带来治疗益处。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月5日； 16：1512867。 doi：10.3389/fimmu.2025.1512867。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：癌症免疫学和肿瘤学中的个性化精度医学（PPPM）是一个迅速发展的领域，具有巨大的潜力。胶质瘤以其预后不佳而闻名，在最致命的脑肿瘤中排名最高。尽管取得了进步，但仍然需要精确，个性化的治疗策略。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对来自TCGA和GEO数据库的RNA-Seq和微阵列数据进行了全面分析，并补充了来自神经胶质瘤患者的单细胞RNA测序（SCRNA-SEQ）数据。通过与基础实验整合单细胞测序分析，我们研究了肿瘤进展过程中神经胶质瘤细胞亚群中的分子变异和细胞相互作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们的单细胞测序分析揭示了神经胶质瘤细胞亚群的不同基因表达模式。值得注意的是，分化轨迹分析将NUSAP1确定为末端亚群的关键标记。我们发现，NUSAP1表达升高与预后不良相关，从而通过细胞和动物研究促使其功能作用进一步研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：基于NUSAP1的风险模型可作为个性化神经胶质瘤治疗的预测和治疗工具的潜力。对NUSAP1在胶质母细胞瘤中的机制的深入探索可以增强我们对其对免疫疗法反应的理解，这表明靶向NUSAP1可能会为神经胶质瘤患者带来治疗益处。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39975552/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975552</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835852/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835852</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1512867>10.3389/fimmu.2025.1512867</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39975552</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Meng-Yu Zhao</dc:creator><dc:creator> Zhao-Lei Shen</dc:creator><dc:creator>洪顿戴</dc:creator><dc:creator>Wan Yan Xu</dc:creator><dc:creator> li-na王</dc:creator><dc:creator>Yugu</dc:creator><dc:creator> Jie-Hui Zhao</dc:creator><dc:creator>天阳</dc:creator><dc:creator>Cun-Zhi Wang</dc:creator><dc:creator> Jia-Feng Xu</dc:creator><dc:creator>关恩·陈</dc:creator><dc:creator>董陈</dc:creator><dc:creator>温敏洪</dc:creator><dc:creator>方张</dc:creator><dc:date>2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>单细胞测序阐明了神经胶质瘤中NUSAP1的机制及其诊断和预后意义</dc:title><dc:identifier>PMID：39975552</dc:identifier><dc:identifier> PMC：PMC11835852</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1512867</dc:identifier></item><item><title>鲁唑替尼与调节性T细胞协同作用以改善炎症，但在减少SLE的蛋白尿没有附加的好处</title><link/>https://pubmed.ncbi.nlm.nih.gov/39975551/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250220071941＆v = 2.18.0.post9+e462414<description> CONCLUSIONS: Our results demonstrate that the addition of ruxolitinib to UCB-Tregs increases UCB-Tregs suppressor function and their persistence in vivo, downregulates systemic inflammation, and controls cutaneous SLE but does not add to UCB-Treg-mediated improvement in renal manifestations. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 5;16:1449693. doi: 10.3389/fimmu.2025.1449693.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Umbilical cord blood (UCB)-derived CD4 <sup>+</sup> CD25 <sup>+</sup> CD127 <sup>low</sup> regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: <i>In vitro</i> cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their <i>in vivo</i> combination. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In a dose-dependent manner, ruxolitinib addition synergizes with UCB-Tregs to suppress SLE-PBMC proliferation, inhibit CD8 <sup>+</sup> T cells, and reduce phosphorylation of STAT3/STAT5/AKT in CD8 <sup>+</sup> T cells. UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood <i>in vivo</i> and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. Compared to control, significantly lesser CD3 <sup>+</sup> , CD4 <sup>+</sup> , CD8 <sup>+</sup> , and Ki-67 <sup>+</sup> infiltrates are observed in the lung and kidney of UCB-Tregs and/or ruxolitinib recipients. No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our results demonstrate that the addition of ruxolitinib to UCB-Tregs increases UCB-Tregs suppressor function and their persistence <i>in vivo</i> , downregulates systemic inflammation, and controls cutaneous SLE but does not add to UCB-Treg-mediated improvement in renal manifestations.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39975551/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975551</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11836023/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11836023</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1449693>10.3389/fimmu.2025.1449693</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39975551</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Mi-Ae Lyu</dc:creator><dc:creator> Ximing Tang</dc:creator><dc:creator> Maria Gabriela Raso</dc:creator><dc:creator> Meixian Huang</dc:creator><dc:creator> Ke Zeng</dc:creator><dc:creator> Tara Sadeghi</dc:creator><dc:creator> Christopher R Flowers</dc:creator><dc:creator> Simrit Parmar</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE</dc:title><dc:identifier> pmid:39975551</dc:identifier><dc:identifier> pmc:PMC11836023</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1449693</dc:identifier></item><item><title> Dental problems and oral microbiome alterations in ulcerative colitis</title><link/> https://pubmed.ncbi.nlm.nih.gov/39975550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250220071941&amp;v=2.18.0.post9+e462414<description> Ulcerative colitis is a chronic disease that has not well-established etiology. The role of microbial dysregulation in its pathogenesis has been recently highlighted. Overall, microbiome alterations concern the reduction of bacterial abundance and diversity, resulting in gut microbiome imbalance negatively affecting immunological aspects. There is a link between ulcerative colitis and the oral microbiome. The changes of oral microbiome are found at many levels, from gently dysbiotic composition... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 5;16:1502605. doi: 10.3389/fimmu.2025.1502605.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Ulcerative colitis is a chronic disease that has not well-established etiology. The role of microbial dysregulation in its pathogenesis has been recently highlighted. Overall, microbiome alterations concern the reduction of bacterial abundance and diversity, resulting in gut microbiome imbalance negatively affecting immunological aspects. There is a link between ulcerative colitis and the oral microbiome. The changes of oral microbiome are found at many levels, from gently dysbiotic composition to the presence of the main periodontal microbes. The analysis of oral microbiome can be a part of personalized medicine due to the fact that it is a potential biomarker. Patients with ulcerative colitis may manifest dental symptoms/problems, such as periodontitis (strongly related to the red-complex pathogens- <i>Porphyromonas gingivalis</i> , <i>Tannerella forsythia</i> , <i>Treponema denticola</i> , and bacteria belonging to the other complexes, such as <i>Fusobacterium nucleatum</i> and <i>Aggregatibacter actinomycetecomitans</i> ), dental caries, oral ulcerations, leukoplakia, halitosis, and others. Notably, the DMFT (Decayed, Missing, Filled Teeth) index is higher in these patients compared to healthy subjects. According to some data, oral lichen planus (which is a disease with an immunological background) can also be observed in ulcerative colitis patients. It seems that deep understanding of ulcerative colitis in association with oral microbiome, immunology, and dental manifestations may be crucial to provide complex treatment from a dental point of view.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39975550/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975550</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11836005/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11836005</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1502605>10.3389/fimmu.2025.1502605</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39975550</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Robert Kucharski</dc:creator><dc:creator> Bartosz Kamil Sobocki</dc:creator><dc:creator> Ewa Stachowska</dc:creator><dc:creator> Nikola Bulman</dc:creator><dc:creator> Leszek Kalinowski</dc:creator><dc:creator> Karolina Kaźmierczak-Siedlecka</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>Dental problems and oral microbiome alterations in ulcerative colitis</dc:title><dc:identifier> pmid:39975550</dc:identifier><dc:identifier> pmc:PMC11836005</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1502605</dc:identifier></item><item><title> Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase</title><link/> https://pubmed.ncbi.nlm.nih.gov/39975549/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250220071941&amp;v=2.18.0.post9+e462414<description> The factors contributing to the treatment efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in the maintenance phase are unknown. Here, we collected blood samples from patients with SLE (n=44) treated with belimumab before and three and six months after treatment. RNA-Seq of whole blood was performed, and gene expression was quantified. Immune cell type enrichment analysis estimated immune cell subtype proportions and gene expression in each subtype. The Systemic Lupus... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 5;16:1506298. doi: 10.3389/fimmu.2025.1506298.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The factors contributing to the treatment efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in the maintenance phase are unknown. Here, we collected blood samples from patients with SLE (n=44) treated with belimumab before and three and six months after treatment. RNA-Seq of whole blood was performed, and gene expression was quantified. Immune cell type enrichment analysis estimated immune cell subtype proportions and gene expression in each subtype. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) &lt; 4 at six months was set as the primary efficacy criterion. Non-responders exhibited upregulated B cell proliferation signals before treatment, associated with an increased number of memory B cells. A higher proportion of memory B cells before treatment predicted poor response ( <i>p</i> =5.1×10 <sup>-4</sup> ). This was also associated with changes in disease activity and glucocorticoid dose at six months compared with baseline. Belimumab did not affect memory B cell proportion during the treatment time course, in contrast to naïve B cells. Higher memory B cell proportion was associated with higher type-I interferon (IFN) scores and lower white blood cell and complement C4 levels. Transcriptomic analysis of memory B cells in non-responders revealed significant upregulation of immunoglobulin genes (Ig). Memory B cells and high Ig expression in them were identified as a treatment-resistant factor of belimumab in SLE patients. Lower C4 and white blood cell counts may serve as clinical markers of higher memory B cells.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39975549/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975549</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835923/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835923</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1506298>10.3389/fimmu.2025.1506298</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39975549</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Takeshi Iwasaki</dc:creator><dc:creator> Hajime Yoshifuji</dc:creator><dc:creator> Koji Kitagori</dc:creator><dc:creator> Shuji Sumitomo</dc:creator><dc:creator> Shuji Akizuki</dc:creator><dc:creator> Ran Nakashima</dc:creator><dc:creator> Hideaki Tsuji</dc:creator><dc:creator> Ryosuke Hiwa</dc:creator><dc:creator> Mirei Shirakashi</dc:creator><dc:creator> Kosaku Murakami</dc:creator><dc:creator> Akira Onishi</dc:creator><dc:creator> Hideo Onizawa</dc:creator><dc:creator> Masao Tanaka</dc:creator><dc:creator> Fumihiko Matsuda</dc:creator><dc:creator> Akio Morinobu</dc:creator><dc:creator> Koichiro Ohmura</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase</dc:title><dc:identifier> pmid:39975549</dc:identifier><dc:identifier> pmc:PMC11835923</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1506298</dc:identifier></item><item><title> Polymorphisms in immunosuppression-related genes are associated with AML</title><link/> https://pubmed.ncbi.nlm.nih.gov/39975548/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250220071941&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Our findings on SNP associations in AML immunosuppression-related genes provide important reference points for predicting treatment outcomes in AML patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 5;16:1530510. doi: 10.3389/fimmu.2025.1530510.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Acute myeloid leukemia (AML) is a hematologic malignancy with poor overall survival (OS). The immunosuppressive microenvironment significantly impacts AML development and chemoresistance. Despite new immunotherapeutic strategies entering standard clinical care for various tumors, progress in AML remains poor. Multi-omics analyses, such as single-cell transcriptomics, have revealed many potential new targets to improve AML prognosis from an immunological perspective. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: DNA from 307 AML patients and 316 healthy individuals were extracted. We detected nine single nucleotide polymorphisms (SNPs) in five immunosuppression-related genes (CIITA, CD200, CD163, MRC1 and LILRB4) in these samples. SNP genotyping was performed on the MassARRAY platform. We then analyzed the relationship between these SNPs and AML susceptibility, treatment response, and prognosis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Our findings indicated that rs4883263 in the CD163 gene is a protective factor for AML susceptibility and chromosomal karyotype abnormalities. Additionally, rs4883263 in CD163 was related to low PLT count at diagnosis, while rs2272022 in CD200 was protective against low PLT count. rs4780335 in CIITA was associated with high WBC count at diagnosis and worse OS. Furthermore, rs1048801 in LILRB4 was linked to worse AML treatment response, lower OS, and may be an independent prognostic risk factor for AML. Lastly, expressions of CD163, CIITA, LILRB4, and CD200 were higher in AML patients than that in normal controls. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our findings on SNP associations in AML immunosuppression-related genes provide important reference points for predicting treatment outcomes in AML patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39975548/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975548</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835863/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835863</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1530510>10.3389/fimmu.2025.1530510</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39975548</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Mingying Li</dc:creator><dc:creator> Jingjing Ye</dc:creator><dc:creator> Mengyuan Chang</dc:creator><dc:creator> Lei Feng</dc:creator><dc:creator> Tingting Liu</dc:creator><dc:creator> Di Zhang</dc:creator><dc:creator> Yuyan Wu</dc:creator><dc:creator> Yuechan Ma</dc:creator><dc:creator> Guangqiang Meng</dc:creator><dc:creator> Chunyan Ji</dc:creator><dc:creator>陶太阳</dc:creator><dc:date>2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>Polymorphisms in immunosuppression-related genes are associated with AML</dc:title><dc:identifier> pmid:39975548</dc:identifier><dc:identifier> pmc:PMC11835863</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1530510</dc:identifier></item><item><title> Understanding HLA-DQ in renal transplantation: a mini-review</title><link/> https://pubmed.ncbi.nlm.nih.gov/39975547/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250220071941&amp;v=2.18.0.post9+e462414<description> Human leukocyte antigen (HLA) mismatching, particularly with HLA-DQ, significantly impacts the development of donor-specific antibodies (DSA) and transplant outcomes. HLA-DQ antibodies are highly immunogenic and detrimental, necessitating advanced high-resolution HLA typing to improve mismatch assessment and clinical risk evaluation. Traditional serological or low-resolution typing often misclassifies mismatches, leading to inaccuracies in assessing immunogenicity and predicting outcomes.... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 5;16:1525306. doi: 10.3389/fimmu.2025.1525306.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Human leukocyte antigen (HLA) mismatching, particularly with HLA-DQ, significantly impacts the development of donor-specific antibodies (DSA) and transplant outcomes. HLA-DQ antibodies are highly immunogenic and detrimental, necessitating advanced high-resolution HLA typing to improve mismatch assessment and clinical risk evaluation. Traditional serological or low-resolution typing often misclassifies mismatches, leading to inaccuracies in assessing immunogenicity and predicting outcomes. Emerging molecular mismatch algorithms refine immunogenicity assessments by analyzing amino acid differences and structural interactions. These tools show promise for personalizing transplant protocols but have limitations, such as variability in predicting individual patient outcomes. Immunogenicity of mismatches also depends on evolutionary divergence and specific amino acid differences, with studies revealing that certain evolutionary lineages and polymorphisms influence T-cell alloreactivity and DSA development. Complexities in HLA-DQ protein expression, including combinatorial diversity of heterodimers and inter-isotypic heterodimers, further complicate risk evaluation. Expression levels, influenced by tissue specificity and inflammatory stimuli, and alternative splicing of HLA-DQ transcripts add additional layers of variability. Future clinical applications, enabled by high-resolution HLA typing, may include refined graft selection, improved DSA monitoring, and individualized therapy. However, understanding the precise mechanisms of HLA-DQ immunogenicity remains a priority for advancing transplantation science and enhancing patient outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39975547/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">39975547</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11835797/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250220071941&v=2.18.0.post9+e462414">PMC11835797</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1525306>10.3389/fimmu.2025.1525306</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39975547</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Rajdeep Das</dc:creator><dc:creator> Neil S Greenspan</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>免疫学领域</dc:source><dc:title>Understanding HLA-DQ in renal transplantation: a mini-review</dc:title><dc:identifier> pmid:39975547</dc:identifier><dc:identifier> pmc:PMC11835797</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1525306</dc:identifier></item></channel></rss>